home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9410o.zip
/
M94A2869.TXT
< prev
next >
Wrap
Text File
|
1994-10-25
|
3KB
|
48 lines
Document 2869
DOCN M94A2869
TI Efficacy of ZDV/DDC measured by surrogate markers.
DT 9412
AU Banhegyi D; Ujhelyi E; Gerlei Z; Fust G; Saint Laszlo Hospital Dept. of
Immunology, Budapest, Hungary.
SO Int Conf AIDS. 1994 Aug 7-12;10(1):206 (abstract no. PB0255). Unique
Identifier : AIDSLINE ICA10/94369706
AB OBJECTIVES: In a pilot study of the multicenter safety and tolerance
study (M50002) the efficacy of ZDV/DDC (zidovudine/dideoxycytidine)
combination were investigated by means of clinical signs and surrogate
markers. METHODS: 15 patients (pts) who had been treated with ZDV (mean
24.5 months; 16-40) and had disease progression in the last 6 month of
treatment entered into this ZDV/DDC combination study. Pts were treated
with 250 mg ZDV b.i.d. and 0.75 mg DDC t.i.d., according to the study
design pts who developed mild adverse reactions were able to continue
the treatment with a reduced dosage of DDC (0.375 mg t.i.d.). Six months
before and during the 6 months of ZDV/DDC trial surrogate markers as
CD4+ cells (absolute and percentage), serum p24 antigen, neopterin and
beta-2-microglobulin as well as Karnofsky index, clinical progression
were investigated. RESULTS: In group A: responder (AUCS of CD4+ > 110%,
and either elevation of raw CD+ or CD+%) were 5 pts. In group B: stabile
(AUCS of CD4+ 100 +/- 9%%, and no significant decrease in either of raw
CD4+ or CD4+%) were 4 pts. In group C: non-responder (decrease in AUCS,
absolute and percentage of CD4+) were 4 pts. There were two drop-outs.
Neither progression to AIDS nor new AIDS defining diseases were
observed. Dosage reduction of DDC was necessary in four pts out of whom
three belonged to group A. Using other surrogate markers; in group A
supported the improvement, where as in group B and C they were
inconclusive. CONCLUSIONS: The introduction of ZDV/DDC therapy in pts
with longer ZDV monotherapy and disease progression can benefit of this
combination-therapy. Pts with CD4+ cell counts higher then 100/microL
are more likely to take advantage of the combination.
DE beta 2-Microglobulin/*ANALYSIS Antiviral Agents/ADMINISTRATION &
DOSAGE/ADVERSE EFFECTS/ *THERAPEUTIC USE Biopterin/*ANALOGS &
DERIVATIVES/BLOOD Comparative Study Drug Therapy, Combination Human
HIV/ISOLATION & PURIF HIV Core Protein p24/*BLOOD HIV
Infections/BLOOD/*DRUG THERAPY *Karnofsky Performance Status Leukocyte
Count Pilot Projects Safety Treatment Outcome *T4 Lymphocytes
Viremia/MICROBIOLOGY Zalcitabine/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS/*THERAPEUTIC USE Zidovudine/ADMINISTRATION & DOSAGE/ADVERSE
EFFECTS/*THERAPEUTIC USE CLINICAL TRIAL MEETING ABSTRACT MULTICENTER
STUDY
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).